Coxsackievirus B Compositions and Methods Of Use Thereof
AssigneeVactech Oy
InventorsHeikki Hyöty, Mikael Knip, Francisco Leon
Life of this patent
Estimating the term…
Abstract
The present disclosure provides coxsackievirus B (CVB) compositions and methods of use of such compositions to induce an immune response to CVB in an individual.
Claims26
A composition comprising coxsackievirus B (CVB) of from two to five serotypes, wherein the CVB is the form of inactivated viral particles (IVP), viral-like particles (VLP), one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides, wherein the composition comprises:
- A) two or more of:
- a) CVB1 in an amount of from 2.0×107 IVP to 5.0×107 IVP;
- b) CVB2 in an amount of from 1.0×107 IVP to 3.0×107 IVP;
- c) CVB3 in an amount of from 1.0×108 IVP to 3.0×108 IVP;
- d) CVB4 in an amount of from 2.0×107 IVP to 5.0×107 IVP;
- and
- e) CVB5 in an amount of from 4.0×107 IVP to 8.0×107 IVP,
- or an equivalent amount of VLP, one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides,
- in a volume of 100 μL;
- or
- B) two or more of:
- a) CVB1 in an amount of from 1.0×108 IVP to 2.5×108 IVP;
- b) CVB2 in an amount of from 5.0×107 IVP to 1.5×108 IVP;
- c) CVB3 in an amount of from 5.0×108 IVP to 1.5×109 IVP;
- d) CVB4 in an amount of from 1.0×108 IVP to 2.5×108 IVP;
- and
- e) CVB5 in an amount of from 2.0×108 IVP to 4.0×108 IVP,
- or an equivalent amount of VLP, one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides,
- in a volume of 500 μL;
- or
- C) two or more of:
- a) CVB1 protein in an amount of from 1 μg to 50 μg;
- b) CVB2 protein in an amount of from 1 μg to 50 μg;
- c) CVB3 protein in an amount of from 1 μg to 50 μg;
- d) CVB4 protein in an amount of from 1 μg to 50 μg;
- and
- e) CVB5 protein in an amount of from 1 μg to 50 μg,
- wherein the composition does not include CVB6.
-5. (canceled)
(canceled)
A composition comprising coxsackievirus B (CVB) of from two to five serotypes, wherein the CVB is the form of inactivated viral particles (IVP), a CVB viral-like particle (VLP), one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides wherein the composition, when administered to an individual, induces viral neutralizing antibody titer (VNT) of from 1/8 to 1/64,000 as determined by a VNT assay, wherein the composition does not include CVB6.
-12. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.